Monoclonal antibody (MAb) 4DS was used to analyze the phosphorylation of p185HER2, the gene product of c-erbB-21HER2, in SK-BR-3 cells. Culture in the continuous presence of 4DS reduced the in vivo steady-state levels of p185HER2 phosphorylation by 80% in a dose-dependent manner, suggesting that MAb 4DS may have interfered with the activation of phosphorylation of p185HER2. The observed MAb-mediated reduction of p185HER2 phosphorylation could not be completely accounted for by down-regulation. When cultures were grown under serum-free conditions, the steady-state levels ofpl85HER2 phosphorylation were reduced by 56%, and addition of 4DS further inhibited phosphorylation to 20% of steady-state levels. With continuous exposure to increasing concentrations of newborn calf serum in these cultures, the. re was a linear increase in tyrosine-specific phosph~lation of p185HER2, reaching a 5.4-fold increase with 10% newborn calf serum. Phosphorylation of pl85H R2 in the presence of newborn calf serum was not attributable to stimulation of the epidenna1 growth factor receptor by epiderma1 growth factor or by transforming growth factor-a. Extension of these observations to two other mammary carcinoma ceU lines, MDA·MB-453 and BT-474, a1so demonstrated a significant capacity of serum to induce pl85HER2 phosphorylation. The demonstration of antibody· mediated partial inhibition of phosphorylation under serum-free conditions suggests that mammary carcinoma cells may also produce and secrete a factor or factors which may activate l185HER2. Our observation that growth-inhibitory MAb 4DS is able to reduce the phosphorylation of p185HB by newborn calf serum and by a cellular-derived factor(s) suggests the existence of a growth factor(s) which uses phosphorylation of p185HER2 as a signal transduction pathway to regulate ceU proliferation.
Monoclonal antibody (MAb) 4DS was used to analyze the phosphorylation of p185HER2, the gene product of c-erbB-21HER2, in SK-BR-3 cells. Culture in the continuous presence of 4DS reduced the in vivo steady-state levels of p185HER2 phosphorylation by 80% in a dose-dependent manner, suggesting that MAb 4DS may have interfered with the activation of phosphorylation of p185HER2. The observed MAb-mediated reduction of p185HER2 phosphorylation could not be completely accounted for by down-regulation. When cultures were grown under serum-free conditions, the steady-state levels ofpl85HER2 phosphorylation were reduced by 56%, and addition of 4DS further inhibited phosphorylation to 20% of steady-state levels. With continuous exposure to increasing concentrations of newborn calf serum in these cultures, the. re was a linear increase in tyrosine-specific phosph~lation of p185HER2, reaching a 5.4-fold increase with 10% newborn calf serum. Phosphorylation of pl85H R2 in the presence of newborn calf serum was not attributable to stimulation of the epidenna1 growth factor receptor by epiderma1 growth factor or by transforming growth factor-a. Extension of these observations to two other mammary carcinoma ceU lines, MDA·MB-453 and BT-474, a1so demonstrated a significant capacity of serum to induce pl85HER2 phosphorylation. The demonstration of antibody· mediated partial inhibition of phosphorylation under serum-free conditions suggests that mammary carcinoma cells may also produce and secrete a factor or factors which may activate l185HER2. Our observation that growth-inhibitory MAb 4DS is able to reduce the phosphorylation of p185HB by newborn calf serum and by a cellular-derived factor(s) suggests the existence of a growth factor(s) which uses phosphorylation of p185HER2 as a signal transduction pathway to regulate ceU proliferation.
Proto-oncogenes are a group of normal genes which play important roles in the regulation of cell proliferation and function (2, 5) . Abnormalities in the expression , structure, or activity of proto-oncogene products contribute to the development and maintenance of the malignant phenotype in complex but important ways (36, 37, 46) . Evidence that the gene products of several activated proto-oncogenes are either growth factors or growth factor receptors has suggested a possible link between proto-oncogenes and growth factors (20) . For example, the receptor for macrophage colony-stimulating factor is identical to the product of c-fms (35) , and c-erbB-1 encodes the receptor for epidermal growth factor (13) and transforming growth factor-a (TGF-a) (43) . Growth factor receptors encoded by proto-oncogenes are transmembrane glycoproteins with intrinsic tyrosine-kinase activity (22) . Receptor tyrosine kinases are activated by binding of their respective ligands, the growth factors (48) . This activity is thought to be an integral part of signal transduction processes involved in the regulation of cell proliferation (21) . Overexpression of some growth factor receptors has been shown to induce transformed properties in recipient ceUs (11, 32) , possibly because of excessive activation of signal transduction mechanisms. Furthermore, a number of tumor cells with increased expression of growth factor receptors also produce ligands for these receptors (10) .
HER2 (also known as c-erbB-2 or c-neu), the human • Corresponding author.
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homolog of the rat proto-oncogene neu (9), encodes a 185-kDa transmembrane glycoprotein with intrinsic tyrosine kinase activity which is presumed to be the receptor for an as-yet-unidentified ligand (3, 39) . pl85HERz also has homology to, but is distinct from , the epidermal growth factor receptor (EGF-R), which is the product of c-erbB-1. Both proteins have a cysteine-rich extracellular domain, a transmembrane domain, and an intracellular tyrosine kinase (4, 31 , 47) . In spite of sequence homology between c-erbB-2 and c-erbB-1, EGF does not bind to pl85HERz (33) . pl85HERz has been shown to be overexpressed or amplified or both in a number of human malignancies: breast (45), ovarian (38) , thyroid (1), lung (7) , salivary gland (34) , and stomach (50) . In addition, pl85HER2 is a potent oncogene capable of inducing transformation and tumorigenesis when overexpressed in NIH 3T3 ceUs (12, 19) . Overexpression of pl85HER2 also induces tumor cell resistance to macrophage killing (15) . Thus p185HERZ may have an important role in the development and maintenance of human tumors.
These observations suggest that receptor-associated tyrosine kinase activity of overexpressed proto-oncogene protein products is important for the regulation of cell growth. We have developed a panel of monoclonal antibodies (MAbs) reactive with domains of the human EGF-R (23) and p185HER2 (17, 18) in intact ceUs and have demonstrated antiproliferative effects of these antibodies in vitro (16, 18, 23) and in vivo (29) . Antibody 405 , which is specifically directed against pl85HERZ, exhibits strong antiproliferative activity on cultured human breast tumor cell lines which overexpress pl85HER2 (18) . Since p185H.ER2 is a receptor with intrinsic tyrosine kinase activity, we investigated the modula'.i-Jn of p185HERi phosphorylation by MAb 405. We report here that activation of phosphorylation of p185HERi by serum was reduced in the presence of an excess of MAb 405 and that MAb-sensitive phosphorylation was mediated by a growth factor or factors other than TGF-o: or EGF. Furthermore, SK-BR-3 cell-conditioned medium contained a factor(s) that could activate pl85HERi phosphorylation and was partially inhibited by MAb 405 . (3 x  10 5 ) were plated in F-12/DMEM in each well of a six-well dish. Twenty-four hours later, cultures were washed with phosphate-free medium and incubated for up to 15 h in phosphate-free F-12/DMEM containing 0.4 mCi of 32 P; per ml in the presence or absence of MAb and newborn calf serum. At desi.red times, cells were harvested in 400 µI of lysis buffer (20 mM HEPES [N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid; pH 7.5), 1% Triton X-100, 10% glycerol, 1.5 mM magnesium chloride, 1 mM ethyleneglycol bis-N,N,N' ,N'-tetraacetic acid, 0.1 mM phenylmethylsulfonyl fluoride , 10 µg of leupeptine per ml , 2 mM sodium orthovanadate) at 4°C for 20 min. The lysate was centrifuged at 10,000 rpm in an Eppendorf microfuge for 10 min, and then 60 µl of Pansorbin was added as described elsewhere (42 the 185-kDa HER2 protein, resolved as described above, was excised out of the gel. 32 P-labeled pl85HERz in a gel slice was partially hydrolyzed with 200 µI of 6 N HCI at ll0°C for 1 h. Two portions (10 µleach) of the hydrolysate were taken for measurement of radioactivity in a liquid scintillation counter to determine the total incorporation of 32 P into the pl85HER 2 receptor. The rest of the hydrolysate was dried, suspended in distilled water, and applied to a Dowex AG1-X8 column. The column was washed with distil.led water, and the absorbed 32 P-labeled materials were eluted with 0.5 N HCI and lyophilized. The recovery of radioactivity by this procedure was 78 to 85%.
MATERIALS AND METHODS

Materials
32 P-phosphoamino acids mixed with unlabeled carrier phosphoamino acids (phosphoserine, phosphoth.reonine, and phosphotyrosine [1:1:1)) were analyzed by thin-layer electrophoresis as described elsewhere (8) .
RESULTS
MAb 405 reduces amount of 32 P-labeled pl8SH£R 2 • MAb 4D5 was used to investigate the regulation of phosphorylation. SK-BR-3 cells, which have an amplified c-erbB-2 gene (45), were cultured for 15 h in medium containing 32 P; in the continuous presence of various concentrations of MAb 4D5. The pl85/fERi from these cells was immunoprecipitated with another anti-p185H£Ri MAb, 906, which recognizes a distinct epitope of p185HERz, and resolved by SOS-polyacrylamide gel electrophoresis. Results of such an experiment are shown in Fig. 1 . Treatment of cells with 4D5 reduced in vivo steady-state levels of 32 P-labeled p185HERi up to 80% in a dose-dependent manner (lanes 2 through 4). There was 49% ± 8% reduction in phosphorylation by 150 nM MAb 405 in eight different experiments. When the F(ab) fragment of 4D5 was used instead of intact antibody, comparable or greater reduction of 32 P-labeled p185HER 2 was observed (lane 5). As a control, SK-BR-3 cells were incubated with another MAb, 225 lgGI, specifically directed against the EGF-R, and there was no effect on the amount of 3 2 P-labeled pl85He:Ri (unpublished data). The reduction in steady-state levels of 32 tibody (18) recognizing the carboxy-terminal 17 amino acids of pl85HER 2 gave similar results (unpublished data). Next , we examined the possibility of general inhibitory effects of MAb 405 on the steady-state levels of other 32 P-labeled receptor proteins by analyzing the amount of 32 P-labeled pl85HER.Z and 32 P-labeled EGF-R in the same experiment (Fig. 2) . These results indicated that there was no reduction of 32 P-labeled EGF-R during 15 h of treatment of SK-BR-J cells with 150 nM MAb 405. which had reduced the amount of 32 P-labeled p l85HER by 48%. Analysis of reduction of pl8SH£Rz phosphorylation. The reduction of steady-state levels of 32 P-labeled pl85HERi by MAb 405, shown in Fig. 1 and 2 , could result from downregulation of pl85HER 2 and/or interference in the activation of pl85HER2 phosphorylation by a direct or indirect m1:chanism(s). In initial studies to explore these possibilities. parallel cultures of cells were metabolically labeled with [3 5 S)cysteine or 32 P;. During 11 h of concurrent incubation with MAb 405 , there was a 45% reduction in 32 P-labeled pl85HERZ (Fig. JA) and only a 14% reduction in JSS-labeled pl85HERZ (Fig. JB) . This suggests that the reduced 32 (Fig. 2) . The expression ofEGF-R was not affected. Immunoblotting of similar unlabeled SK-BR-J extracts also demonstrated very little reduction in the content of pl85HERi by MAb 405 (Fig. J D, experiment 2) . These findings indicate that increased receptor catabolism induced by a MAb cannot fully account for the observed red uction in 32 P labeling and show £with F(ab)) that reduced labeling is dissociated from reduced content of pl85HER~.
Next we addressed the possibility that the reduction in 32 P-labeled pl85HER.Z associated with exposure to MAb 405 could be related to a change in the level of expression of pl85HERi on the plasma membrane or to the extent of PETITIONER'S EXHIBITS 3) or with culture medium (lane 1). Samples were prepared and immunoprecipitation was carried out as described in Materials and Methods. An autorad iogram of a dried gel is shown here. Quantitation of the p185H£Rl bands was obtained by densitometric scanning (A through C) or by determining radioactivity associated with bands (A and 8 ). Quantitation by determining the radioactivity assoc iated with pl85H£R1 bands in panels A and B gave results similar to tho~e with den sitometric scanning, and there was a 27% :!: 3% additional red11c1infl in 32 P-labeled pl85H£Rl compared with "S-labeled pl85H£Hl . ID) lmmunoblotting of pl85H£Rl and EGF-R proteins. In experiment 1 (Exp. I).
32 P-labeled SK-BR-3 cell extracts (50 µ.g of pMteinl used in Fig. 2 . lanes 1 and 2. were resolved on a 7"K SDS-p0lyac rylamide gel and then immunoblotted with anti-Pl85 M:\b 9G6 or aati-EGF-R p0lyclonal antibody RK-11. Experiment 2 ~hows the immunoblotting of unlabeled S K-BR-3 cell extracts µrepared following culture for 15 h with or without 30 nM MAb 405. Since some of the extracts used here were radiolabeled. immunoblotted membranes were visualized by using a protein A-gold ..:11ru1ni:ement kit i30). Abs. AntibvJu:s. ERz is present on the cell surface at J7°C (Fig. 4A) analyzed the effect of incubation with MAb 405 at 4°C. In these studies, cells were first equilibrated with 32 P 1 for 4 h at 37°C (Fig. 4B, lane 1) and then maintained at 37°C (lanes 2 and 3) or shifted to 4°C (lanes 4 and 5) for an additional 11 h , with or without MAb 405. A comparison of the labeled material in lanes 2 and 4 in Fig. 4B (ftuorographs exposed for 24 and % h, respectively) showed a significant 85% reduction in 32 P labeling of pl85HERi during 11 h at 4°C compared with labeling at 37°C. However, incubation of cells at 4°C did not prevent a further substantial MAb-mediated reduction in steady-state levels of pl85HERi phosphorylation: there was a 34% decrease at 4°C (compare lanes 4 and 5) and a 51% decrease at 37°C (compare lanes 2 and 3). Taken together, these observations indicate that MAb-induced reduction in pl85HER phosphorylation cannot be completely accounted for by down-regulation.
Experiments were performed to determine whether the F(ab) fragment might have the capacity to act as an agonist by activating tyrosine phosphorylation. The results in Fig. 5 indicate that the addition of F(ab) for 15 min sli_ghtly stimulated in vivo tyrosine phosphorylation of pl85 E R i in cultures labeled with 32 P (Fig. 5, lane 2' ). However, there was no activation in cultures exposed to F(ab) for a longer treatment of 60 min (Fig. 5 , lane 3 ' ). The observation that the F(ab) fragment of 405 does not down-regulate the 35 S- labeled pl85HERi but can act for a short time as a partial agonist is interesting; however, we have not attempted to further characterize these properties in the present study.
PETITIONER'S EXHIBITS
Activation of phosphorylation of p18SHER2 in presence or absence of newborn calf serum. Next, we investigated the possible source of the factor(s) that might stimulate pl85HERi phosphorylation. As shown in Fig. 6A , culturing the cells in serum-free medium resulted in a steady-state level of phosphorylation of p185
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2 reduced 56% (lane 1) compared with that observed in the continuous presence of newborn calf serum (lane 3). The addition of MAb 405 in serum-free culture conditions further reduced pl85HERi A. phosphorylation (Fig. 6A, lane 2) to 20% of the steady-state levels achieved in the absence of newborn calf serum (Fig.  6A , Jane 1). Experiments were done to examine the capacity of newborn calf serum to stimulate tyrosine phosphorylation ofp185H£Rl in short-term ~eatment. There was no increased activation of phosphorylation when serum-free cultures were supplemented with newborn calf serum for 30 min at 37 or 4°C (data not shown).
To determine the specificity of the ca~city of newborn calf serum to stimulate activation of p185 . ERZ phosphorylation in SK-8R-3 cells, we investigated the potential for serum activation of another closely related molecule, the EGF-R. There was no potentiating effect of newborn calf serum on phosphorylation of the EGF-R in SK-8R-3 cells (Fig. 68) .
Ravi~ shown an increase in the steady-state levels of p185H£ phosphorylation induced by newborn calf serum and its reduction by MAb 405, we determined the phosphoamino acid content of p185H£Ri under these conditions by two-dimensional thin-layer electrophoresis (Fig. 6C) . p185HER2 from Cells Cultured in the absence Of newborn Calf serum contained predominantly pbosphoserine and phosphotlireonine with little phosphotyrosine (Fig. 6C, blot 1) . The presence of some phosphorylatio~ on tyrosine can be demonstrated by longer exposure of the autoradiogram but is not visualized well in the figure shown. Quantitation of the relative amount of label in each amino acid was obtained by scraping the ninhydrin-ideiltified spots from the thin-layer plate for liquid scintillation counting. Activation by 5% newborn calf serum increased the total phosphoamino acid content 2.2-fold, while for phosphotyrosine, the increase was 3.9-fold (Fig. 6C, blot 2) . Inhibition of newborn calf serum-mediated stimulation ofpl85H£Ri phosphorylation by MAb 405 resulted in a parallel reduction in the content of all three phosphoamioo acids (Fig. 6C, blot 3) .
Tyrosine phosphorylation or pl85 8 ER2 . To further quantitate tlie relative increase in the steady-state phosphotyrosine content of pl85H£RZ induced by newborn calf serum, cells were metabolically labeled with [3 5 S]cysteine and assayed for the steady:state phosphotyrosine content of p185HERl by using antiphosphotyrosine MAb PY-69. MAb PY-69 was specific for pbospbotyrosine in the immunoprecipitation reaction; i.e. , we were able to show competion for binding with cold phosphotyrosine and not with phosphoserine in experiments with 35 S-labeled EGF-R (data not shown). As illustrated in Fig. 7 A, lanes 1' to 4 ', the amount of phosphorylation of p185HERi on tyrosine increased with the concentration of newborn calf serum in the culture medium. The level of activation of tyrosine phosphorylation in serum-free medium was 18% of that observed in 10% newborn calf serum , and in medium containing 2.5% serum, tyrosine phosphorylation was 35% of that observed with a serum concentration of 10%. As a control, equal amounts of labeled cell extracts were immunoprecipitated with anti-pl85HER2 MAb 9G6 (Fig. 7 A, lanes I through 4) . There was no significant effect of serum on the levels of 35 S-labeled pl85H£RZ in the cells. To quantitate these results, the ratios of phosphotyrosine-associated counts to total counts associated with p185 8 £R2 are presented in Fig. 78 , which shows a dose-dependent increase of up to 5.4-fold with 10% newborn calf serum in the culture medium.
Partial depletion of activating factor from newborn calf serum. Since our results indicated the presence of some activating factor(s) for p185H£R2 phosphorylation in newborn calf serum, we sought confirmation of this observation by determining whether newborn calf serum could be de-
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P-Tyr To quantitate the data in panel A, the radioactivity associated with p185HER1 was determined by counting the excised bands in a liquid scintillation counter. The ratios of counts in pl85H£Rz phosphotyrosine over total counts in pl85H~ were plotted as a percentage of control with 0% newborn calf serum against the concentration of newborn calf serum used in the culture medium. (C) Depletion of the activator(s) of p18SHER1 phosphorylation in serum. SK-BR-3 cells were labeled with 32 P 1 in the absence or presence of serum for 15 h. Lane l, Control without serum; lane 2, medium with 5% newborn calf serum; lane 3, medium with 5% newborn calf serum depleted of factor(s) by three repetitive adsorptions of 4 h each on SK-BR-3 cells at 4"C; lane 4, control medium adsorbed on A431 cells. Cell extracts were prepared and p185HER1 was assayed as described in Materials and Methods.
pleted of such a factor(s). In these experiments, phosphatefree medium containing 5% newborn calf serum was treated by repetitive absorption with SK-8R-3 cells (three times, for 4 h each time, at 4°C). Culture medium treated in an identical manner by adsorption with A431 cells, which do not express high levels of pl85"£R2, was used as control. Figure 7C shows that there was a 53% reduction in p185 8 £R2 phosphorylation in SK-8R-3 cells cultured in the presence of medium preadsorbed with SK-8R-3 cells (lane 3) compared with untreated medium (lane 2), and there was only a 16% reduction in p185HERi phosphorylation when SK-8R-3 cell cultures were supplemented with medium preadsorbed with A431 cells (Fig. 7C, lane 4) . Activation factor(s) In newborn calf serum was not TGF-o or EGF. pl85H£Ri has been shown to be phosphorylated when EGF-Rs are activated by ex~sure to EGF or TGF-a, which are not ligands for pl85 88 (24, 40) . To determine whether the newborn calf serum-mediated 2.2-fold enhancement of pl85HER2 phosphorylation resulted from the activity ofTGF-a or EGF, we used anti-EGF-R MAb 528, which bas Exhibit 1088 Page 5 of 8 Activation of pl85HERl by newborn calf serum was not due to TGF-a or EGF. Subconfluent SK-BR-3 cells were labeled with 32 P 1 for 15 h in the presence or absence of 5% newborn calf serum, 150 oM MAb 405, and 300 nM MAb 528. As a positive control, some cultures received 40 nM TGF-a either alone (column 6) or with 300 nM MAb 528 (column 7) during the last 20 min of labeling. Cells were lysed and then immunoprecipitated with MAb 9G6 to assay pl85HERJ. The insert displays the autoradiogram resulting from a 3-h exposure of the dried gel. To quantitate the amounts of pl85H~, protein bands were excised for determining the radioactivity, which is represented here on an arbitrary scale. These experiments were performed three times.
been shown to block the binding of EGF and TGF-a to their receptors (23, 25) . The experiment whose results are shown in Fig. 8 demonstrates that coincubation of SK-BR-3 with a saturating amount of anti-EGF-R MAb 528 did not significantly alter the ca)Jacity of newborn calf serum to increase the levels of pl85 ERJ phosphorylation. As a positive control, some cultures received TGF-a with or without MAb 528 during the last 20 min of labeling before cells were harvested , and MAb 528 completely blocked the predicted and observed increases in phosphorylation of pl85HERi induced by TGF-a (Fig. 8, column 6 and 7) .
Observations with other mammary carcinoma cells. In order to determine whether activation of p185HER2 phosphorylation by newborn calf serum and its inhibition by MAb 405 are phenomena restricted to SK-BR-3 cells or whether they can be demonstrated with other breast tumor cells overexpressing pl85HER 2 , we extended our investigation to two other lines: MOA-MB-453 and BT-474. The results in Fig. 9 indicate a significant capacity of newborn calf serum to activate p185HER2 phosphorylation and show that the addition of MAb 405 could reduce the steady-state levels of p185HER2 phosphorylation both in the presence of newborn calf serum and in serum-free cultures. growth factors transduce signals that activate cell proliferation (6, 22, 27, 48) . Support for this model is provided by our experiments demonstrating growth inhib ition of cells overexpressing EGF-Rs by MAbs 225 and 528, which recognize these transmembrane receptors on intact cells, prevent binding of the growth factor-ligand, and block ligand-induced phosphorylation of EGF-Rs (16, 23, 29) . A similar antiproliferative effect has been observed when SK-BR-3 cells, which overexpress p185RERi , are exposed to MAb 405 (17, 18) . The present work was undertaken to explore the modulation of phosphorylation of pl85HeRz by an antipl85HERZ MAb, 405, and by newborn calf serum.
The results presented here indicate that treatment of SK-BR-3 cells with MAb 405 significantly reduced the steady-state levels of phospho~lation of the c-erbB-21 HER2/ c-neu gene product p185H£R on serine, threonine, and tyrosine residues. Anti-p185H£Ri MAb has been shown to cause enhanced down-regulation of pl85HERi from the surface of human and murine cells by reducing the half-life of pl85HERZ (14, 18) . Our conclusion that MAb 405-mediated inhibition of the steady-state levels of pl85HER2 phosphorylation was only in part attributable to the down-regulation of p185H£R2 is supported by the following lines of evidence: (i) the reduction of phosphorylation was far in excess of the reduced content of 32 S-labeled protein measured by immunoprecipitation and also by immunoblotting; {ii) inhibition of phosphorylation was observed at 4°C under conditions in which MAb-induced down-regulation of p185HERz wouJd be limited; (iii) the inhibitory effect of MAb 405 on pl85HER2 phosphorylation could be mimicked by F(ab) fragment, which does not down-regulate pl85HER2. The last observation is similar to findings with the F(ab) fragment of another MAb-specific murine p185HERJ (14) . Taken together, these data provide strong indirect evidence that MAb 405 may have interfered with the activation of phosphorylation of pl85HER2 by a growth factor(s).
The observation that newborn calf serum contains an activator(s) of phosphorylation of pl85HER2 opens a new area of investigation for identifying an additional factor(s) which might stimulate pl85HERZ phosphorylation. This capacity of newborn calf serum to activate phosphorylation was specific for p185HER2; it did not affect the phosphorylation of EGF-Rs in SK-BR-3 cells. The fact that newborn calf serum was not able to stimulate p185HER2 phosphorylation in short-term treatment raises the possibi.lity of some indirect mechanism of p185 11 ER2 activation by newborn calf serum, or it could be a matter of quantity of the responsible factor(s). The evidence that newborn calf serum has the capacity to stimulate tyrosine-specific phosphorylation preferentially in p185HER2 (in addition to serine and threonine phosphorylation) is of special interest, as it strongly suggests that this serum probably contains a growth factor(s) capable of activating transduction of a known growth-regulating signal in cells.
Data from the literature and from this work suggest that p185HER2 may also be phosphorylated by exposing cells to TGF-a or EGF, probably as a result of activation of EGF-R tyrosine kinase (24, 40) . However, interaction with EGF-Rs was not responsible for the observed newborn calf serummediated activation of p185 11 ER2 phosphorylation, since addition of MAb 528 did not alter the activation potential of newborn calf serum, although it blocked TGF-a-induced increase in p185HER2 phosphorylation. Moreover, our finding that serum was able to activate the phosphorylation of p185HER2 in MDA-MB-453 provides additional evidence against possible involvement of TGF-a or EGF in the observed serum-mediated activation of pl85HERz phosphorylation, since these cells do not have receptors that bind labeled EGF (49) and since p185HER2 phosphorylation is not activated in these cells by EGF (24, 49) .
The reduced phosphorylation of p185HERz observed when MAb 405 was added to serum-free cultures of SK-BR-3, MDA-MB-453, and BT-474 cells also suggests that under these conditions it may have blocked activation of p185
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ERZ phosphorylation by a cellular-derived factor(s) produced by these human mammary carcinoma cells. This view is further supported by our preliminary observations (data not shown) that under the appropriate conditions, SK-BR-3-conditioned medium can inhibit the binding of the growth-inhibitory MAb 405 but not the binding of another MAb, 6E9, which recognizes a distinct epitope on the extracellular domain of the receptor and has no effect on tumor cell growth (18) . Additional evidence for a cellular-derived factor is provided by Lupu et al. (28) , who have recently identified a polypeptide which is constitutively secreted in small amounts by SK-BR-3 cells and competes with MAb 405 for binding sites on the surface of SK-BR-3 cells.
The observation that MAb 405, which reduces the proliferation of cells bearing pl85HERZ, is able to inhibit the capacity of both newborn calf serum and a constitutive activity to increase levels of pl85HERz phosphorylation suggests the existence of a growth factor or factors for p185HERZ which may use receptor phosphorylation as a signal transduction pathway to regulate cell growth.
